Education
About Us
Working with TipRanks
Follow Us
Nrx Pharmaceuticals, Inc. (NRXP)
:NRXP
NRXP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.10 - $6.01
Previous CloseN/A
Volume2.07M
Average Volume (3M)234.09K
Market Cap
$35.18M
Enterprise Value$23.57M
Total Cash (Recent Filing)$11.08K
Total Debt (Recent Filing)$690.00K
Price to Earnings (P/E)―
Beta0.31
Next Earnings
May 20, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.41
Shares Outstanding16,915,648
10 Day Avg. Volume211,124
30 Day Avg. Volume234,087
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.23
Forecast
1Y Price Target
$19.00Price Target Upside813.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
NRX Pharmaceuticals News
PremiumCompany Announcements
NRX Pharmaceuticals Reports 2024 Financial Results and Strategy
PremiumCompany Announcements
NRx Pharmaceuticals’ Earnings Call: Progress Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
Business StrategyNRx Pharmaceuticals has made significant advances in its business strategy, including progress with an abbreviated New Drug Application filing for NRX-100 and an NDA filing for accelerated approval of NRX-101.
Clinical TrialsNRX-100 has shown highly significant reductions in suicidal ideation in clinical trials, suggesting its effectiveness as a treatment.
Market PotentialThe anti-suicide market, where NRx Pharmaceuticals is targeting with NRX-100, is projected to reach $5 billion by 2026, growing at a 4% compound annual growth rate.
Bears Say
Financial PerformanceThe company reported a net loss of $7.9 million or EPS of $(0.75), missing consensus estimates.
Market CompetitionThere is no medicine approved to treat patients with bipolar depression suffering suicidal ideation, presenting a large market potential.
Profitability ChallengesNRx Pharmaceuticals is targeting achievement of $100M in revenue in 2025 and could become profitable with just $38M in revenue.
---
Ownership Overview
8.97% Insiders
1.82% Mutual Funds
3.11% Other Institutional Investors
82.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NRXP FAQ
What was Nrx Pharmaceuticals, Inc.’s price range in the past 12 months?
Nrx Pharmaceuticals, Inc. lowest stock price was $1.10 and its highest was $6.01 in the past 12 months.
What is Nrx Pharmaceuticals, Inc.’s market cap?
Nrx Pharmaceuticals, Inc.’s market cap is $35.18M.
When is Nrx Pharmaceuticals, Inc.’s upcoming earnings report date?
Nrx Pharmaceuticals, Inc.’s upcoming earnings report date is May 20, 2025 which is in 56 days.
How were Nrx Pharmaceuticals, Inc.’s earnings last quarter?
Nrx Pharmaceuticals, Inc. released its earnings results on Mar 17, 2025. The company reported -$0.7 earnings per share for the quarter, missing the consensus estimate of -$0.367 by -$0.333.
Is Nrx Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Nrx Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Nrx Pharmaceuticals, Inc. pay dividends?
Nrx Pharmaceuticals, Inc. does not currently pay dividends.
What is Nrx Pharmaceuticals, Inc.’s EPS estimate?
Nrx Pharmaceuticals, Inc.’s EPS estimate is -0.32.
How many shares outstanding does Nrx Pharmaceuticals, Inc. have?
Nrx Pharmaceuticals, Inc. has 16,915,648 shares outstanding.
What happened to Nrx Pharmaceuticals, Inc.’s price movement after its last earnings report?
Nrx Pharmaceuticals, Inc. reported an EPS of -$0.7 in its last earnings report, missing expectations of -$0.367. Following the earnings report the stock price went down -12.766%.
Which hedge fund is a major shareholder of Nrx Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in NRXP
---
NRX Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.00 (813.46% Upside)
$19.00 (813.46% Upside)
Hedge Fund Trend
Increased
By 50.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $46.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.5%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-58.82%
12-Months-Change
Fundamentals
Return on Equity
108.28%
Trailing 12-Months
Asset Growth
-50.09%
Trailing 12-Months
Company Description
Nrx Pharmaceuticals, Inc.
Big Rock Partners Acquisition Corp. is a blank check company, which was formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, reorganization, recapitalization or other similar business combination with one or more businesses or entities. It focuses on identifying a prospective target business in the senior housing and care industry in the United States. The firm's care segments are commonly divided into four categories: Independent Living; Assisted Living; Memory Care and Nursing Care. The company was founded on September 18, 2017 and is headquartered in Delray Beach, FL.
---
NRXP Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in drug development, potential strategic partnerships, and financial improvements, particularly with the expansion of HOPE Therapeutics. However, challenges remain due to the unsupportive capital market environment, low cash reserves, and regulatory complexities in clinic acquisitions. Despite these challenges, the positive developments and strategic initiatives outweigh the negatives.Read More>---
NRXP Stock 12 Month Forecast
Average Price Target
$19.00
▲(813.46% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Alaunos Therapeutics
―
Karyopharm Therapeutics
―
Evolus
―
Atea Pharmaceuticals
―
Best Analysts Covering NRXP
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
-19.64%
reiterated a buy rating 4 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -19.64% per trade.
---